Company / Revenue
Inhibrx Biosciences, Inc. Revenue History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.3M
FY2025
5-year range
$1.3M / $1.8M
FY2023-FY2025
Trend
-27.8%
vs FY2024
Sector context
#146 of 155
Health Care
What the data says
Among 155 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 6% for revenue. Declined from $2M to $1M over the past 2 years.
Based on SEC 10-K filings.
$1M in FY2025.
Declined from $2M to $1M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 155This company $1.3M Sector average $4.5B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, revenue decreased 27.8% year-over-year.
- Ranks #146 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | -27.8% |
| FY2024 | $1.8M | +0.0% |
| FY2023 | $1.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026